AngioDynamics Reports $7.1 Million Net Loss and 6.9% Revenue Growth in Q1 FY 2027

AngioDynamics, Inc. reported a net loss of $7.1 million for the first quarter of fiscal year 2027, a significant improvement from the $10.9 million loss recorded in the same period last year. The company’s revenue increased by 6.9% to $80.9 million, compared to $75.7 million in the prior year. This growth was driven by a 13.2% increase in the Med Tech segment, which includes products like Auryon and NanoKnife, and a modest 1.4% growth in the Med Device segment. The gross margin also improved, rising to 59.4% from 55.3% a year earlier, reflecting better sales volume and product mix.

In terms of operational metrics, AngioDynamics saw a notable increase in sales across its product lines. The Med Tech segment generated $39.9 million in sales, up from $35.3 million, while the Med Device segment brought in $41.0 million, slightly up from $40.5 million. The company’s international sales remained stable at approximately 12.2% of total sales, with no single international customer accounting for more than 10% of total revenue. The company’s backlog stood at $2.7 million as of August 31, 2026, indicating potential future sales.

AngioDynamics has also made strategic investments in research and development, with R&D expenses increasing to $8.0 million from $6.4 million year-over-year. This investment is aimed at enhancing existing products and developing new technologies. The company’s total operating expenses rose to $55.3 million, up from $52.5 million, primarily due to increased spending in sales and marketing, which reflects the company’s focus on expanding its market presence.

The company’s cash position has decreased, with cash and cash equivalents totaling $34.0 million as of August 31, 2026, down from $53.9 million at the end of the previous fiscal year. This decline is attributed to cash used in operating activities, which amounted to $15.3 million for the quarter. Despite this, AngioDynamics maintains that its current cash balance, along with cash generated from operations and access to a $25 million revolving credit facility, will provide sufficient liquidity for at least the next 12 months.

Looking ahead, AngioDynamics is optimistic about its growth trajectory, driven by ongoing product innovation and geographic expansion. The company plans to continue investing in R&D and exploring strategic partnerships to enhance its product offerings and market reach. The recent appointment of Eric Honroth as President and CEO is expected to bring fresh leadership and direction as the company navigates the evolving healthcare landscape.